Core Viewpoint - Oscar Health, Inc. (OSCR) is showing potential for a bullish trend as it has recently broken above the 50-day moving average, indicating a key level of support [1]. Group 1: Technical Indicators - The 50-day simple moving average is a significant marker for traders and analysts to identify support or resistance levels, and OSCR's recent breakout suggests a short-term bullish trend [2]. - Over the past four weeks, OSCR shares have increased by 13.8%, indicating positive momentum [2]. Group 2: Earnings Estimates - Positive revisions in earnings estimates for OSCR strengthen the bullish outlook, with no estimates decreasing in the past two months and three estimates increasing [3]. - The consensus estimate for OSCR has also risen, further supporting the case for potential growth [3]. Group 3: Investment Consideration - Given the technical indicators and positive earnings estimate revisions, OSCR is recommended for investors to consider adding to their watchlist [3].

分组1 - UnitedHealth's share price has decreased by 8% following a downgrade to a 'Hold' rating due to disappointing Q4 earnings, which led to a selloff [1] - The current stock performance reflects the challenges faced by UnitedHealth in meeting market expectations [1] 分组2 - The analyst has a beneficial long position in UnitedHealth shares, indicating a personal investment interest [2] - The article expresses the analyst's own opinions and is not influenced by compensation from any company mentioned [2]

Core Viewpoint - Oscar Health's stock rose nearly 2% due to unexpectedly optimistic guidance for the fourth quarter, despite missing analyst estimates on trailing results [1] Financial Performance - Oscar's total revenue for Q4 2025 was $2.8 billion, reflecting a 17% increase from the previous year [2] - The company's net loss deepened to approximately $353 million ($1.24 per share) from a loss of nearly $154 million in Q4 2024 [2] Analyst Expectations - Analysts had projected Oscar to perform better, with average revenue estimates at $3.1 billion and a net loss estimate of $0.89 per share [4] Membership Growth - Oscar reported a significant increase in membership, with total members exceeding 2 million, up from under 1.7 million in the same period last year [4] Future Outlook - The company provided a bullish full-year revenue guidance of $18.7 billion to $19 billion, with operational earnings projected between $250 million and $450 million [7] - This revenue projection is significantly higher than the consensus analyst estimate of under $12.8 billion [8]

Core Viewpoint - Centene Corporation reported a fourth-quarter adjusted loss despite revenue exceeding Wall Street expectations, primarily due to high costs in the Commercial segment, leading to a more than 6% drop in shares following the announcement [1]. Financial Performance - The company recorded an adjusted loss of $1.19 per share for the quarter, which was slightly better than analyst expectations of a $1.22 loss [2]. - Revenue increased by 23% year over year to $49.73 billion, surpassing the consensus estimate of $48.39 billion [2]. - The consolidated health benefits ratio (HBR) rose sharply to 94.3%, compared to 89.6% in the same quarter last year [2]. Segment Analysis - The Commercial segment had an HBR of 95.4%, which was approximately 100 basis points above company expectations due to net out-of-period items [3]. - The Medicaid segment showed improvement with an HBR of 93.0%, reflecting a 40-basis-point sequential improvement from the third quarter [3]. Future Guidance - For the full year 2025, Centene reported adjusted earnings of $2.08 per share on revenue of $194.78 billion, indicating a 20% increase compared to 2024 [4]. - The company provided guidance for 2026, projecting adjusted earnings per share of more than $3.00, demonstrating confidence in its recovery efforts [4].

Core Viewpoint - UnitedHealth Group is facing challenges due to rising medical costs impacting its financial performance, despite offering a relatively attractive dividend yield of 3% compared to the S&P 500's average yield of 1.1% [2][8]. Financial Performance - UnitedHealth's revenue for the year reached $447.6 billion, reflecting a 12% year-over-year increase, but earnings from operations declined by 41%, totaling just under $19 billion [4]. - The company incurred significant expenses related to restructuring, workforce reductions, and a previous cyberattack, contributing to the decline in earnings [5]. Future Outlook - The company projects earnings from operations to improve to $24 billion for the upcoming year, with an expected operating cash flow of at least $18 billion, down from $19.7 billion [6]. - UnitedHealth is expected to pay approximately $8 billion in dividends over the year, which appears manageable given the anticipated cash flow and capital expenditures [7]. Dividend Safety - Current indicators suggest that UnitedHealth's dividend is safe, as the expected cash flow should cover capital expenditures of $3.8 billion and share repurchases of $2.5 billion, alongside dividend payments [7]. - Despite the attractive dividend yield, the stock has seen a decline of over 40% in the past three years, raising concerns about future growth and persistent high costs [8].

Core Viewpoint - UnitedHealth Group (NYSE: UNH) has shown a significant bullish technical signal with the formation of its first golden cross since July 2024, indicating potential recovery after a substantial earnings-driven decline [1][3]. Stock Performance - UNH stock has experienced a peak-to-trough decline of approximately 48%, trading around $287, down from highs above $550 in 2024 [2]. - The stock saw a sharp drop of about 20% in January 2026 following disappointing Q4 2025 earnings and a weaker outlook for 2026 [3]. Technical Indicators - The 50-day moving average recently crossed above the 200-day moving average, suggesting improving short-term momentum after a prolonged bearish trend [1][3]. - The $330–$350 price zone remains a critical resistance level that needs to be reclaimed for a sustainable trend reversal [4]. Financial Performance - UnitedHealth reported Q4 2025 revenue of $113.2 billion, which fell short of expectations by approximately $530 million [4]. - Although adjusted EPS of $2.11 met forecasts, the focus was on underlying weaknesses, particularly the 2026 revenue guidance projected at over $439 billion, significantly below the consensus of around $454 billion [5]. - This guidance indicates a rare year-over-year revenue decline from 2025's revenue of about $447.6 billion, challenging previous growth assumptions [6].

Core Viewpoint - UnitedHealth Group's stock experienced a significant decline of nearly 20% following a Q4 earnings report that showed a minor sales miss and a drastic drop in GAAP profits, which fell nearly 100% year over year to just $0.01 per share [1]. Group 1: Earnings Report Impact - UnitedHealth's non-GAAP earnings met analyst expectations, but GAAP earnings were severely disappointing [1]. - The stock is showing signs of recovery, with a 4% increase noted the following day, although this is minimal compared to the previous day's losses [3]. Group 2: Analyst Reactions - Following the earnings report, seven analysts have lowered their price targets for UnitedHealth stock, yet all still value it above the current trading price of $294 [4]. - Analysts' price targets vary, with Bank of America setting a target of $315 and Cantor Fitzgerald predicting a rise to $440, indicating a potential 50% profit from current levels [6]. Group 3: Investment Considerations - UnitedHealth stock is trading at 16.7 times forward earnings and offers a 3.1% dividend yield, with expectations to triple profits over the next five years [6]. - Despite the recent downturn, the stock is still viewed as a buy by most analysts [5].

Core Viewpoint - Elevance Health has forecasted that its profit for 2026 will be below Wall Street expectations due to anticipated higher medical costs continuing into the year [1] Group 1: Financial Forecast - The company expects that elevated medical costs will persist, impacting profitability [1] - The profit forecast for 2026 is notably lower than what analysts had anticipated [1]

Earnings Reports - Boeing (BA) reported a Q4 loss of -$1.91 per share after excluding a one-time sale of Digital Aviation Solutions for $10.55 billion, with revenues up +57% year over year to $23.95 billion [1] - UnitedHealth (UNH) beat earnings estimates by 2 cents at $2.11 per share, but revenues fell slightly by -0.04% to $113.22 billion, leading to a pre-market share drop of -15% [2] - General Motors (GM) exceeded earnings expectations with $2.51 per share, a +14% beat, and reported quarterly revenues of $45.29 billion, down -1.83%, while announcing a +20% increase in dividends [3] - United Parcel Service (UPS) posted earnings of $2.38 per share on revenues of $24.48 billion, beating estimates by +7.2% and +1.95% respectively, although shares were trading modestly down after initial gains [4] Market Expectations - January Consumer Confidence is anticipated to be reported at 90, slightly above the previous month's 89.1, but still below the 100 points average seen over the past four years, reflecting consumer strain from a delicate labor market and policy shifts [5] Upcoming Earnings - Texas Instruments (TXN) is expected to report Q4 earnings with flat year-over-year growth but a +10.7% increase in revenues, continuing a streak of eight consecutive quarterly earnings beats, with the stock up +13% since the start of the year [6]

Core Viewpoint - UnitedHealth raised its annual profit forecast after reporting better-than-expected quarterly earnings, attributed to effective management of medical costs [1] Company Summary - UnitedHealth reported quarterly earnings that exceeded market expectations, indicating strong financial performance [1] - The company has successfully kept medical costs in check, contributing to its improved profit outlook [1] Industry Summary - The performance of UnitedHealth reflects broader trends in the U.S. health insurance industry, where cost management is becoming increasingly critical for profitability [1]